IBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
IBIO, INC. (IBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.52% for the 9-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2024-05-13
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-09-30 was 4.52%.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2017-09-30 was 2.23%.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2015-09-30 was 2.13%, a 7.39% decline year-over-year.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-09-30 was 2.30%.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 0.60%, a 75.51% decline from fiscal 2019.
- IBIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.45%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2024-03-31 | 4.52% 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | 4.52% 10-Q · filed 2024-02-09 | |||
| 2023-09-30 | 4.52% 10-Q · filed 2023-11-14 | |||
| 2020-06-30 | 0.60% 10-K · filed 2020-10-13 | |||
| 2020-03-31 | 0.66% 10-Q · filed 2020-05-15 | |||
| 2019-06-30 | 2.45% 10-K · filed 2019-08-26 | |||
| 2018-03-31 | 2.23% 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | 2.23% 10-Q · filed 2018-02-14 | |||
| 2017-09-30 | 2.23% 10-Q · filed 2017-11-09 | |||
| 2017-03-31 | 2.37% 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | 2.13% 10-Q · filed 2016-02-22 | |||
| 2015-09-30 | 2.13% 10-Q · filed 2015-11-13 | |||
| 2014-09-30 | 2.30% 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |